Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 12 weeks (3HP) by directly observed therapy (DOT) f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:MMWR. Morbidity and mortality weekly report 2018-06, Vol.67 (25), p.723-726
Hauptverfasser: Borisov, Andrey S., Morris, Sapna Bamrah, Njie, Gibril J., Winston, Carla A., Burton, Deron, Goldberg, Stefan, Woodruff, Rachel Yelk, Allen, Leeanna, LoBue, Philip, Vernon, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
Full Report
HIV
Isoniazid
Patient compliance
Tuberculosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 12 weeks (3HP) by directly observed therapy (DOT) for treatment of LTBI, with limitations for use in children aged
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm6725a5